Anocca Secures EUR 25M from the European Investment Bank
- Anocca, a Södertälje, Sweden-based cell therapy biotechnology company, received €25M in Venture Debt
- The European Investment Bank made the financing
- The company intends to use the funds to move T-cell immunotherapies towards clinical trials in a solid tumour indication
- The company is using technology to engineer next generation T-cell immunotherapies for the treatment of solid tumours
- The company is building libraries of novel T-cell immunotherapies that specifically target difficult to treat cancers and will be moving into clinical trials in 2024
- Alongside oncology, proprietary technologies are being applied to the development of vaccines and treatments for autoimmune diseases
